国泰航空(00293)拟购买30架空中巴士 A330-900 型飞机Zai Lab's net product revenue in the second quarter was $0.1001 billion, a YoY growth of 45%, with cash and cash equivalents of $0.73 billion. Beigene's total revenue in the second quarter reached $0.929 billion, a YoY growth of 56%, achieving non-GAAP operating profit.
Major events:
SSY Group (02005): multiple products have obtained pharmaceutical production registration certificates.
Cathay Pacific Air (00293) plans to purchase 30 Airbus A330-900 aircraft.
Consun Pharma (01681) has obtained pharmaceutical registration approval for Iodophoramine injection.
Shimao Group (00813) subsidiary plans to sell all issued shares of Xiamen Shimao New Navigation Real Estate for 0.59634 billion yuan.
Apollo FMG (00860) plans to sell approximately 12.87% equity of Divergent Technologies for $0.1015 billion and resume trading on August 8th.
SDHS New Energy (01250) has been approved for Guangxi's 400 MW wind power project indicators.
The first patient was administered in the registration-based Phase III clinical study of JAB-3312 in combination with Glecirasib by Gakuso-B (01167).
Business performance:
In the second quarter, zai lab (09688) had a net product revenue of 0.1001 billion US dollars, a 45% year-on-year increase, with cash reserves reaching 0.73 billion US dollars.
China Tower (00788) announced its interim performance, with net income of 5.33 billion yuan, a YoY increase of 10.1%.
u-presid china (00220) announced its semi-annual performance with a net profit of about 0.9657 billion yuan, a year-on-year increase of 10.2%.
Beigene's total revenue in the second quarter reached $0.929 billion, a YoY growth of 56%, achieving non-GAAP operating profit.
Beigene (06160) released its key financial data for the first half of the year, with total revenue of 11.996 billion yuan, a YoY increase of 65.4%.
